CA19-9、CA72-4和CEA在阿帕替尼治疗胃癌患者中的变化及意义

目的 探讨阿帕替尼治疗前后胃癌患者血清糖链抗原19-9(carbohydrate antigen 19-9,CA19-9)、糖链抗原72-4(carbohydrate antigen 72-4,CA72-4)和癌胚抗原(carcinoembryonic antigen,CEA)的变化及其与临床疗效的关系.方法 选取我院收治的62例晚期胃癌患者作为研究对象,回顾性分析阿帕替尼治疗前后患者血清中CA19-9、CA72-4和CEA的水平,并根据临床疗效部分缓解(PR)、稳定(SD)和进展(PD)的例数,计算疾病缓解率(RR)和疾病控制率(DCR),并分为疾病控制(DC)组和非DC组,比较各组治疗前后血清CA19-9、CA72-4和CEA水平变化,并比较两组之间治疗前后各指标水平差异.结果 阿帕替尼治疗后血清CA19-9和CA72-4水平显著降低(P＜0.05),而CEA无显著性变化(P＞0.05).阿帕替尼治疗晚期胃癌的PR率为3.22％,SD率为41.94％,PD率为54.84％.阿帕替尼治疗后,DC组血清CA19-9、CA72-4和CEA水平显著下降(P＜0.05),而非DC组CA19-9、CA72-4无显著性差异(P＞0.05),CEA水平显著升高(P＜0.05).治疗前,DC组和非DC组CA19-9、CA72-4和CEA水平无显著性差异(P＞0.05),治疗后DC组三个指标水平均显著低于非DC组(P＜0.05).对患者用药不良反应发生率分析,结果显示无严重不良反应终止治疗病例.结论 血清CA19-9、CA72-4和CEA水平在阿帕替尼治疗后病情得到控制的胃癌患者中显著降低,可用于阿帕替尼治疗胃癌的效果评价.

The Variations and Significance of CA19-9, CA72-4 and CEA in Patients with Gastric Cancer Before and After Treatment with Apatinib

Objective To explore the variations of serum carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 72-4 (CA72-4) and carcinoembryonic antigen (CEA) in gastric cancer patients before and after treatment with apatinib,and study their relationship with clinical effects.Methods 62 advanced gastric cancer patients were chosen as the objects.Serum contents of CA19-9,CA72-4 and CEA before and after treatment were detected,and remission rate (RR) and disease control rate (DCR) according to the cases of partial remission (PR),stable disease (SD),progressive disease (PD) were calculated.The patients were divided into disease control(DC) group and non-DC group,the serum contents of CA19-9,CA72-4 and CEA before and after treatment were compared in each group,and the difference between the two groups were compared.Results The serum contents of CA19-9 and CA72-4 decreased significantly in gastric cancer patients after treatment with apatinib (P ＜ 0.05),while the content of CEA did not markedly changed (P ＞ 0.05).The rate of PR that apatinib treated advanced gastric cancer was 3.22％,the rate of SD was 41.94％,and the rate of PD was 54.84％.After treatment of apatinib,the contents of CA19-9,CA72-4 and CEA decreased significantly in DC group(P ＜0.05),while the contents of CA19-9 and CA72-4 did not markedly changed (P ＞ 0.05),and the CEA increased significantly in non-DC group (P ＜ 0.05).Before treatment,there was no difference between the DC group and the non-DC group in the contents of CA19-9,CA72-4 and CEA(P ＞0.05),while after treatment,the contents in DC group were significantly lower than that in non-DC group (P ＜ 0.05).Through the analysis of the incidence of adverse drug reactions,there was no case showed serious adverse reactions to terminate treatment.Conclusion The serum contents of CA19-9,CA72-4 and CEA decrease significantly in gastric cancer patients,whose diseases are controlled after treatment with apatinib,and which may be used to evaluate the effects of apatinib on advanced gastric cancer.